LikeMinds is developing a brain imaging agent that is intended to support the early diagnosis of dopamine mediated neurological diseases such as Parkinson’s, Alzheimer’s, ADHD, depression, addiction and schizophrenia.
The facts are clear: 68.5 million Americans require accurate, precise diagnosis of degenerative brain diseases yet current imaging tools lack the required precision and economic value proposition required to bring care to a broad patient population. By example, approximately 11 million Americans are suffering from Parkinson’s or Essential Tremor, with difficulty distinguishing between diagnoses. Ruling out one disorder is paramount for appropriate treatment of the other. Yet, because of the high cost, lengthy procedure time, and low adoption, less than 1% of these patients receive diagnostic imaging related to dopamine activity in their brains.
Without dopamine transporter (DaT) brain imaging, neurologists often misdiagnose and therefore ineffectively treat 50-74% of tremor patients for an average of 4.5 years. Patients suffer through costly, ineffective treatments, doctors are unable to provide appropriate disease management, leading to unnecessary cost to the U.S. healthcare system. The Michael J. Fox Foundation’s recently published research, “The Economic Burden of Parkinson’s Disease”, calculates that the annual cost of care for Parkinson’s patients alone is $52 billion, with an annual government liability of $25 billion.
Enter the LikeMinds solution. LikeMinds’ imaging agent, Altropane, is an innovative 123I labeled tropane molecule that binds with high affinity to dopamine transporters in the brain. Its high selectivity translates into fast DaT imaging procedures intended to result in improved logistics and economics. This will make brain imaging widely available, leading to improved outcomes for patients, physicians, payers and product development companies.
Altropane has completed six tremor disorder clinical trials in more than 500 subjects and has demonstrated a favorable safety and efficacy profile. The upcoming POET 7 clinical trial is designed to establish image quality and utility. The company currently anticipates FDA approval and access to this growing market in late 2021. Through its launch of a best-in-class DaT imaging agent in this important growth area LikeMinds expects annual sales of this class of agents to exceed $1B by 2030.
In the coming decade, market growth will be driven by a rise in disease incidence and prevalence due to demographic and environmental changes. Demand is also predicted to increase dramatically due to new, FDA approved, disease modifying treatments. While these disease modifying therapeutics do not currently exist for Parkinson’s, there are approved treatments available for Essential Tremor, namely MRI Guided High Intensity Focused Ultrasound. When properly diagnosed, this reimbursed treatment can be made available to 90% of tremor patients. LikeMinds’ innovation in selectivity, speed, cost and utility of dopamine imaging, partnered with the advent of other predictive and diagnostic tests, is a game changer for patients with tremor disorders.
 Under U.S. law, a new drug cannot be marketed until it has been investigated in clinical trials and approved by the FDA as being safe and effective for the intended use Statements included in this presentation that are not historical in nature are “forward looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. This is an investigational drug candidate and all claims are speculative.
For information, please contact Vicki Zikopoulou at [email protected]ds.com.